These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 25131591)

  • 61. Transmission of α-synuclein-containing erythrocyte-derived extracellular vesicles across the blood-brain barrier via adsorptive mediated transcytosis: another mechanism for initiation and progression of Parkinson's disease?
    Matsumoto J; Stewart T; Sheng L; Li N; Bullock K; Song N; Shi M; Banks WA; Zhang J
    Acta Neuropathol Commun; 2017 Sep; 5(1):71. PubMed ID: 28903781
    [TBL] [Abstract][Full Text] [Related]  

  • 62. From Synaptic Physiology to Synaptic Pathology: The Enigma of α-Synuclein.
    Nordengen K; Morland C
    Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38256059
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Alpha-Synuclein and LRRK2 in Synaptic Autophagy: Linking Early Dysfunction to Late-Stage Pathology in Parkinson's Disease.
    Lamonaca G; Volta M
    Cells; 2020 Apr; 9(5):. PubMed ID: 32365906
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Phospholipase D1 downregulation by α-synuclein: Implications for neurodegeneration in Parkinson's disease.
    Conde MA; Alza NP; Iglesias González PA; Scodelaro Bilbao PG; Sánchez Campos S; Uranga RM; Salvador GA
    Biochim Biophys Acta Mol Cell Biol Lipids; 2018 Jun; 1863(6):639-650. PubMed ID: 29571767
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Loss of α-Synuclein Does Not Affect Mitochondrial Bioenergetics in Rodent Neurons.
    Pathak D; Berthet A; Bendor JT; Yu K; Sellnow RC; Orr AL; Nguyen MK; Edwards RH; Manfredsson FP; Nakamura K
    eNeuro; 2017; 4(2):. PubMed ID: 28462393
    [TBL] [Abstract][Full Text] [Related]  

  • 66. alpha-Synuclein at the synaptic gate.
    Surmeier DJ
    Neuron; 2010 Jan; 65(1):3-4. PubMed ID: 20152107
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Synaptic protein alterations in Parkinson's disease.
    Pienaar IS; Burn D; Morris C; Dexter D
    Mol Neurobiol; 2012 Feb; 45(1):126-43. PubMed ID: 22205299
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Cell Biology and Pathophysiology of α-Synuclein.
    Burré J; Sharma M; Südhof TC
    Cold Spring Harb Perspect Med; 2018 Mar; 8(3):. PubMed ID: 28108534
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Membrane insertion exacerbates the α-Synuclein-Cu(II) dopamine oxidase activity: Metallothionein-3 targets and silences all α-synuclein-Cu(II) complexes.
    Calvo JS; Mulpuri NV; Dao A; Qazi NK; Meloni G
    Free Radic Biol Med; 2020 Oct; 158():149-161. PubMed ID: 32712192
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Value of cerebrospinal fluid α-synuclein species as biomarker in Parkinson's diagnosis and prognosis.
    Parnetti L; Cicognola C; Eusebi P; Chiasserini D
    Biomark Med; 2016; 10(1):35-49. PubMed ID: 26643452
    [TBL] [Abstract][Full Text] [Related]  

  • 71. HtrA2 regulates α-Synuclein-mediated mitochondrial reactive oxygen species production in the mitochondria of microglia.
    Nam MK; Seong Y; Jeong GH; Yoo SA; Rhim H
    Biochem Biophys Res Commun; 2023 Jan; 638():84-93. PubMed ID: 36442236
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Alpha-Synuclein Dopaminylation Presented in Plasma of Both Healthy Subjects and Parkinson's Disease Patients.
    Zhao H; Huang S; Palanisamy S; Wang C; Rainer G; Zhang X
    Proteomics Clin Appl; 2020 Sep; 14(5):e1900117. PubMed ID: 32538547
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Microglia in Parkinson's Disease.
    Ho MS
    Adv Exp Med Biol; 2019; 1175():335-353. PubMed ID: 31583594
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Iron and other metals in the pathogenesis of Parkinson's disease: Toxic effects and possible detoxification.
    Bjørklund G; Hofer T; Nurchi VM; Aaseth J
    J Inorg Biochem; 2019 Oct; 199():110717. PubMed ID: 31369907
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Alpha-synuclein and dopamine metabolism.
    Yu S; Uéda K; Chan P
    Mol Neurobiol; 2005; 31(1-3):243-54. PubMed ID: 15953825
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The Search for a Peripheral Biopsy Indicator of α-Synuclein Pathology for Parkinson Disease.
    Lee JM; Derkinderen P; Kordower JH; Freeman R; Munoz DG; Kremer T; Zago W; Hutten SJ; Adler CH; Serrano GE; Beach TG
    J Neuropathol Exp Neurol; 2017 Jan; 76(1):2-15. PubMed ID: 28069931
    [TBL] [Abstract][Full Text] [Related]  

  • 77. α-Synuclein in Parkinson's disease.
    Stefanis L
    Cold Spring Harb Perspect Med; 2012 Feb; 2(2):a009399. PubMed ID: 22355802
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The physiological role of α-synuclein and its relationship to Parkinson's Disease.
    Sulzer D; Edwards RH
    J Neurochem; 2019 Sep; 150(5):475-486. PubMed ID: 31269263
    [TBL] [Abstract][Full Text] [Related]  

  • 79. alpha-Synuclein: a therapeutic target for Parkinson's disease?
    Maguire-Zeiss KA
    Pharmacol Res; 2008; 58(5-6):271-80. PubMed ID: 18840530
    [TBL] [Abstract][Full Text] [Related]  

  • 80. α-Synuclein and Polyunsaturated Fatty Acids: Molecular Basis of the Interaction and Implication in Neurodegeneration.
    Fecchio C; Palazzi L; de Laureto PP
    Molecules; 2018 Jun; 23(7):. PubMed ID: 29941855
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.